Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “ FT-200 Group”) and filed a provisional patent in connection to the…


Previous articleRed Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory
Next articleMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures